Top

Published in:

01-02-2012 | Basic Neurosciences, Genetics and Immunology - Original Article

Preparation and properties of nanoscale containers for biomedical application in drug delivery: preliminary studies with kynurenic acid

Authors: V. Hornok, T. Bujdosó, J. Toldi, K. Nagy, I. Demeter, C. Fazakas, I. Krizbai, L. Vécsei, I. Dékány

Published in: Journal of Neural Transmission | Issue 2/2012

Abstract

The main purpose of this study was to facilitate the delivery of kynurenic acid (KYNA) across the blood–brain barrier (BBB) by applying micelles as nanoscale containers. Non-ionic amphiphilic molecules were used for preparation of spherical micelles for delivery of kynurenic acid in aqueous solution in physiological condition. It was established that Triton X 100 and Lutensol AP 20 non-ionic surfactants are able to produce stable nanocontainers for delivery of kynurenic acid molecules. The incorporation of KYNA molecules was investigated by dynamic light scattering and the size of micelles were calculated between 5 and 10 nm in 150 mM NaCl and pH 7.5–7.6 solutions. Encapsulated kynurenic acid showed a significantly higher blood–brain barrier permeability compared with non-encapsulated kynurenic acid. The in vivo experiments showed that the encapsulated kynurenic acid is able to display effects within the central nervous system, even after its peripheral administration.

Aswal VK, De S, Goyal PS, Bhattacharya S, Heenan RK (1999) Micellar structures of dimeric surfactants with phosphate head groups and wettable spacers: a small-angle neutron scattering study. Phys Rev E 59:3116–3122CrossRef

Dill KA, Koppel DE, Cantor RS, Dill JD, Bendedouch D, Chen SH (1984) Molecular conformations in surfactant micelles. Nature 309:42–45CrossRef

Evans DF, Wennerström H (1994) The colloidal domain—where physics, chemistry, biology and technology meet. VCH Publishers, USA

Fukui S, Schwarz R, Rapaport SI, Takada Y, Smith QR (1991) Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem 56:2007–2017PubMedCrossRef

Gregoriadis G (1995) Engineering liposomes for drug delivery: progress and problems. Trends Biotechnol 13:527–537PubMedCrossRef

Gregoriadis G, Florence AT (1993) Liposomes in drug delivery: clinical, diagnostic and ophthalmic potential. Drugs 45:15–28PubMedCrossRef

Hutamekain P, Farkas AE, Orbok A, Wilhelm I, Nagyoszi P, Veszelka S et al (2008) Effect of nicotine and polyaromtic hydrocarbons on cerebral endothelial cells. Cell Biol Int 32:198–209CrossRef

Iden DL, Allen TM (2001) In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach. Biochim Biophys Acta 1513:207–216PubMedCrossRef

Joshi JV, Aswal VK, Goyal PS (2007) Combined SANS and SAXS studies on alkali metal dodecyl sulphate micelles. J Phys Condens Matter 19:196219CrossRef

Kakudo T, Chaki S, Futaki S, Nakase I, Akaji K, Kawakami T, Maruyama K, Kamiya H, Harashima H (2004) Transferrinmodified liposomes equipped with a pH-sensitive fusogenic peptide: an artificial viral-like delivery system. Biochemistry 43:5618–5628PubMedCrossRef

Kincses ZST, Toldi J, Vécsei L (2010) Kynurenines, neurodegeneration and Alzheimer’s disease. J Cell Mol Med 14:2045–2054PubMedCrossRef

Lindman B, Wennerström H (1980) Topics in current chemistry. Springer, Berlin, p 87

Mastrobattista E, Crommelin DJ, Wilschut J, Storm G (2002) Targeted liposomes for delivery of protein-based drugs into the cytoplasm of tumor cells. J Liposome Res 12:57–65PubMedCrossRef

Mori N, Ohta S (1992) Comparison of anticonvulsant effects of valproic acid entrapped in positively and negatively charged liposomes in amygdaloid-kindled rats. Brain Res 593:329–331PubMedCrossRef

Mori N, Kurokouchi A, Osonoe K, Saitoh H, Ariga K, Suzuki K, Iwata Y (1995) Liposome-entrapped phenytoin locally suppresses amygdaloid epileptogenic focus created by db-cAMP/EDTA in rats. Brain Res 703:184–190PubMedCrossRef

Németh H, Robotka H, Kis Z, Rózsa É, Janáky T, Somlai C, Marosi M, Farkas T, Toldi J, Vécsei L (2004) Kynurenine administered together with probenecid markedly inhibits pentylenetetrazol-induced seizures. Anelectrophysiological and behavioural study. Neuropharmacology 47:916–925PubMedCrossRef

Ostro MJ, Cullis PR (1989) Use of liposomes as injectable-drug delivery systems. Am J Hosp Pharm 46:1576–1587PubMed

Pardridge WM (1998) CNS drug design based on principles of blood–brain barrier transport. J Neurochem 70:1781–1792PubMedCrossRef

Pardridge WM (2002) Drug and gene delivery to the brain: the vascular route. Neuron 36:555–558PubMedCrossRef

Robotka H, Németh H, Somlai C, Vécsei L, Toldi J (2005) Systemically administered glucosamine-kynurenic acid, but not pure kynurenic acid, is effective in decreasing the evoked activity in area CA1 of the rat hippocampus. Eur J Pharamcol 513:75–80CrossRef

Sas K, Párdutz Á, Toldi J, Vécsei L (2010) Dementia, stroke and migraine—some common pathological mechanisms. J Neurol Sci 299:55–65PubMedCrossRef

Stauffer D, Jan N, He Y, Pandey RB, Marangoni DG, Smith-Palmer T (1994) Micelle formation, relaxation time, and three-phase coexistence in a microemulsion model. J Chem Phys 100:6934–6944CrossRef

Stilbs P, Walderhaug H, Lindman B (1983) Micellar fluidity. A deuterium nuclear magnetic resonance spin relaxation study of the anisotropic reorientation of solubilized trans-Decalin-d18. J Phys Chem 87:4762–4769CrossRef

Szleifer I, Ben-Shaul A, Gelbart WM (1987) Statistical thermodynamics of molecular organization in mixed micelles and bilayers. J Chem Phys 86:7094–7110CrossRef

Wilhelm I, Farkas AE, Nagyoszi P, Varo G, Balint Z, Vegh GA et al (2007) Regulation of cerebral endothelial cell morphology by extracellular calcium. Phys Med Biol 52:6261–6274PubMedCrossRef

Wilhelm I, Fazakas C, Krizbai IA (2011) In vitro models of the blood-brain barrier. Acta Neurobiol Exp 71:113–128

Zádori D, Klivényi P, Plangár I, Toldi J, Vécsei L (2011a) Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines. J Cell Mol Med 15:701–717PubMedCrossRef

Zádori D, Nyiri G, Szőnyi A, Szatmári I, Fülöp F, Toldi J et al (2011b) Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington’s disease. J Neural Transm 118:865–875PubMedCrossRef

Title: Preparation and properties of nanoscale containers for biomedical application in drug delivery: preliminary studies with kynurenic acid
Authors: V. Hornok
T. Bujdosó
J. Toldi
K. Nagy
I. Demeter
C. Fazakas
I. Krizbai
L. Vécsei
I. Dékány
Publication date: 01-02-2012
Publisher: Springer Vienna
Published in: Journal of Neural Transmission / Issue 2/2012
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-011-0726-2

At a glance: The STEP trials

Springer Medicine

Preparation and properties of nanoscale containers for biomedical application in drug delivery: preliminary studies with kynurenic acid

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2012

The role of kynurenines in the pathomechanism of amyotrophic lateral sclerosis and multiple sclerosis: therapeutic implications

Kynurenines and the nervous system: therapeutic perspectives

Modifications on the carboxylic function of kynurenic acid

Involvement of kynurenines in Huntington’s disease and stroke-induced brain damage

A novel kynurenic acid analog (SZR104) inhibits pentylenetetrazole-induced epileptiform seizures. An electrophysiological study

Recent rodent models for Alzheimer’s disease: clinical implications and basic research